

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the month of July 2026**

Commission File Number: **001-41923**

**EUPRAXIA PHARMACEUTICALS INC.**  
(Exact name of Registrant as specified in its charter)

**N/A**  
(Translation of Registrant's name)

**2198 Yukon Street**  
**Vancouver, British Columbia, Canada V5Y 3P1**  
**Telephone: (250) 590-3968**  
(Address and telephone number of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [ ☐ ]      Form 40-F [ ☒ ]

---

## DOCUMENTS INCLUDED AS PART OF THIS REPORT

### Exhibit

[99.1](#)      [Material Change Report](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**EUPRAXIA PHARMACEUTICALS INC.**

Date: July 15, 2026

By: /s/ Alex Rothwell  
Name: Alex Rothwell  
Title: Chief Financial Officer

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Company**

Eupraxia Pharmaceuticals Inc. (the “Company”)  
2198 Yukon Street,  
Vancouver, British Columbia,  
Canada, V5Y 3P1

**Item 2: Date of Material Change**

July 13, 2026

**Item 3: News Release**

A news release announcing the material change was issued on July 13, 2026 through Globe Newswire and a copy was subsequently filed on SEDAR+.

**Item 4: Summary of Material Change**

On July 13, 2026, the Company announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

**Item 5.1: Full Description of Material Change**

On July 13, 2026, the Company announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026.

As part of these changes, Dr. Alex Therien, who joined Eupraxia in November 2025, will take the helm of Research & Development in his role as Executive Vice President, Research & Development.

As Eupraxia evolves into a cross-border two-hub organization, Eupraxia has completed the transition of its operations from Victoria to Vancouver and Seattle, reflecting the Company’s focus on supporting its growing clinical operations. Key clinical, manufacturing and commercial executive leadership positions, including the CEO, will be based in the Seattle offices.

As part of this transition, Amanda Malone, based in Victoria, has stepped down from her role as Chief Scientific and Operating Officer, effective July 10, 2026. Eupraxia is grateful for her years of expertise in research and early-stage development.

**Item 5.2: Disclosure of Restructuring Transactions**

Not applicable.

---

**Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7: Omitted Information**

Not applicable.

**Item 8: Executive Officer**

For further information, please contact James A. Helliwell, Chief Executive Officer of the Company at 250-590-3968.

**Item 9: Date of Report**

July 15, 2026